Topics

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

2018-02-08 15:52:10 | BioPortfolio

Summary

This is a single institution, open-label, multi-arm, pilot study assessing the safety, feasibility, and immunogenicity of a personalized neoantigen-based vaccine plus poly-ICLC (NeoVax) combined with immune checkpoint inhibitors in subjects with newly diagnosed, unmethylated glioblastoma.

Study Design

Conditions

Glioblastoma

Intervention

NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research

Location

Washington University School of Medicine
Saint Louis
Missouri
United States
63110

Status

Not yet recruiting

Source

Washington University School of Medicine

Results (where available)

View Results

Links

Published on BioPortfolio: 2018-02-08T15:52:10-0500

Clinical Trials [3822 Associated Clinical Trials listed on BioPortfolio]

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

This research study is studying a new type of personalized neoantigen vaccine (NeoVax) plus Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible tr...

NeoVax With Nivolumab in Patients With Ovarian Cancer

This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.

A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma

This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer. The following intervention ...

Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer

There are 2 parts to this research study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of...

Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)

The goal of this clinical research study is to learn if local consolidation treatment (LCT-- surgery and/or radiation) plus standard chemotherapy (ipilimumab and nivolumab) is more effecti...

PubMed Articles [30008 Associated PubMed Articles listed on BioPortfolio]

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Niv

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis.

Little has been published describing hypophysitis after nivolumab or pembrolizumab treatment. We aimed to (i) assess the risk of hypophysitis following nivolumab or pembrolizumab treatment, (ii) chara...

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year o...

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly a...

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.

CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every 2 ...

Medical and Biotech [MESH] Definitions

Component of the NATIONAL INSTITUTES OF HEALTH. It seeks to improve oral, dental and craniofacial health through research, research training, and the dissemination of health information by conducting and supporting basic and clinical research. It was established in 1948 as the National Institute of Dental Research and re-named in 1998 as the National Institute of Dental and Craniofacial Research.

A designation for publications of research resulting from extramural research funded by the National Institutes of Health.

A designation for publications of research resulting from intramural research at the National Institutes of Health.

The moral obligations governing the conduct of research. Used for discussions of research ethics as a general topic.

Research carried out by nurses in the clinical setting and designed to provide information that will help improve patient care. Other professional staff may also participate in the research.

More From BioPortfolio on "Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma"

Quick Search

Relevant Topics

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...


Searches Linking to this Trial